The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry
Abstract
AIMS: Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds (BVS) in routine clinical practice are limited. To fill this gap, we report on the early and midterm clinical outcomes of PCI with everolimus-eluting BVS from the large multicentre GHOST-EU registry. METHODS AND RESULTS: Between November 2011 and January 2014, 1,189 patients underwent percutaneous coronary intervention with one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 10 European centres. The primary outcome of interest was target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularisation (TLR). A total of 1,731 Absorb BVS were implanted at a mean of 12.3±3.4 atm. Technical success was achieved in 99.7% of cases. TLF was recorded in 67 of 1,189 patients at a median of 109 (interquartile range 8-227) days after implantation. The cumulative incidence of TLF was 2.2% at 30 days and 4.4% at six months. The annualised rate of TLF was 10.1%. At six months, the rate of cardiac death was 1.0%, target vessel myocardial infarction was 2.0%, TLR was 2.5%, and target vessel revascularisation was 4.0%. Diabetes mellitus was the only independent predictor of TLF (hazard ratio 2.41, 95% confidence interval: 1.28-4.53; p=0.006). The cumulative incidence of definite/probable scaffold thrombosis was 1.5% at 30 days and 2.1% at six months, with 16 of 23 cases occurring within 30 days. CONCLUSIONS: "Real-world" outcomes of BVS showed acceptable rates of TLF at six months, although the rates of early and midterm scaffold thrombosis, mostly clustered within 30 days, were not negligible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Palmerini, T., Biondi-Zoccai, G., Riva, D. D., Stettler, C., Sangiorgi, D., D'Ascenzo, F., Kimura, T., Briguori, C., Sabatè, M., Kim, H.-S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60324-9 · Cited by 959
Kolandaivelu, K., Swaminathan, R., Gibson, W. J., Kolachalama, V. B., Nguyen-Ehrenreich, K.-L., Giddings, V. L., Coleman, L., Wong, G. K., & Edelman, E. R. (2011) · Circulation · doi:10.1161/circulationaha.110.003210 · Cited by 802
Drug-Eluting Coronary-Artery Stents
Stefanini, G. G., & Holmes, D. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1210816 · Cited by 728
Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
Serruys, P. W., Silber, S., Garg, S., van Geuns, R. J., Richardt, G., Buszman, P. E., Kelbæk, H., van Boven, A. J., Hofma, S. H., Linke, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004130 · Cited by 670
Self-citationSerruys, P. W., Onuma, Y., Dudek, D., Smits, P. C., Koolen, J., Chevalier, B., de Bruyne, B., Thuesen, L., McClean, D., van Geuns, R.-J., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.050 · Cited by 525
Onuma, Y., & Serruys, P. W. (2011) · Circulation · doi:10.1161/circulationaha.110.971606 · Cited by 434
Holmes, D. R., Kereiakes, D. J., Garg, S., Serruys, P. W., Dehmer, G. J., Ellis, S. G., Williams, D. O., Kimura, T., & Moliterno, D. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.016 · Cited by 367
von Birgelen, C., Basalus, M. W. Z., Tandjung, K., van Houwelingen, K. G., Stoel, M. G., Louwerenburg, J. (. W., Linssen, G. C. M., Saïd, S. A. M., Kleijne, M. A. W. J., Sen, H., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.008 · Cited by 250
Stone, G. W., Kedhi, E., Kereiakes, D. J., Parise, H., Fahy, M., Serruys, P. W., & Smits, P. C. (2011) · Circulation · doi:10.1161/circulationaha.111.031070 · Cited by 201
Cited by
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
Ellis, S. G., Kereiakes, D. J., Metzger, D. C., Caputo, R. P., Rizik, D. G., Teirstein, P. S., Litt, M. R., Kini, A., Kabour, A., Marx, S. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509038 · Cited by 630
Byrne, R. A., Joner, M., & Kastrati, A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv511 · Cited by 609
Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn‐Alloys
Bowen, P. K., Shearier, E. R., Zhao, S., Guillory, R. J., Zhao, F., Goldman, J., & Drelich, J. W. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201501019 · Cited by 544
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI
Wykrzykowska, J. J., Kraak, R. P., Hofma, S. H., van der Schaaf, R. J., Arkenbout, E. K., IJsselmuiden, A. J., Elias, J., van Dongen, I. M., Tijssen, R. Y. G., Koch, K. T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614954 · Cited by 441
Cassese, S., Byrne, R. A., Ndrepepa, G., Kufner, S., Wiebe, J., Repp, J., Schunkert, H., Fusaro, M., Kimura, T., & Kastrati, A. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00979-4 · Cited by 369
Self-citation
Metadata
- Authors
- Capodanno, D., Gori, T., Nef, H., Latib, A., Mehilli, J., Lesiak, M., Caramanno, G., Naber, C., Di Mario, C., Colombo, A., Capranzano, P., Wiebe, J., Araszkiewicz, A., Geraci, S., Pyxaras, S., Mattesini, A., Naganuma, T., Münzel, T., & Tamburino, C.
- Venue
- EuroIntervention
- Publisher
- Europa Digital & Publishing
- Published
- 2015-02
- Volume
- 10
- Issue
- 11
- Pages
- 1144-1153
- ISSN
- 1774-024X (ISSN-L)
- OpenAlex
- W1979793334
- Cited by
- 452
- References
- 19
- FWCI
- 111.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. https://app.cochat.ai/papers/10.4244/eijy14m07_11
- The paper
- Capodanno, D., Gori, T., Nef, H., Latib, A., Mehilli, J., Lesiak, M., Caramanno, G., Naber, C., Di Mario, C., Colombo, A., Capranzano, P., Wiebe, J., Araszkiewicz, A., Geraci, S., Pyxaras, S., Mattesini, A., Naganuma, T., Münzel, T., & Tamburino, C. (2015). Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. https://doi.org/10.4244/eijy14m07_11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.